http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-11201907207U-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3be2429bd1a83fd492acffa31808839c
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6831
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
filingDate 2018-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6f5f5e4e666216e3097ac1d03f604e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3778f739fa3fe8eb786f25a16339e47f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd5e16a49dfb5f7f45624c9551751d14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_243925e72f165f6a01a75a78ffd43ec4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4066bc8b0fc6448fb42a17fecbfefb5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1d58b2069828569bf6aff536b6f2e6d
publicationDate 2019-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber SG-11201907207U-A
titleOfInvention Pharmaceutical combinations comprising an anti-ly75 antibody
abstract HBL14V , O cs\"<\" s. (5 0 1-1 N N N N 1-1 00 O 1-1 N C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT ~~ll~~~~~~~~ 011101010VIIIOH olo VIIIVIII0100111010m 1111101 ois (10) International Publication Number WO 2018/162727 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 47/68 (2017.01) A61P 35/00 (2006.01) A61K 31/505 (2006.01) A61P 35/02 (2006.01) CO7K 16/46 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/EP2018/055939 (22) International Filing Date: 09 March 2018 (09.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1703876.1 10 March 2017 (10.03.2017) GB (71) Applicant: BERLIN-CHEMIE AG [DE/DE]; Glienicker Weg 125-127, 12489 Berlin (DE). (72) Inventors: BINASCHI, Monica; Menarini Ricerche, Via Tito Speri 10 Pomezia, Rome (IT). BIGIONI, Mario; Menarini Ricerche, Via Tito Speri 10 Pomezia, Rome (IT). MERLINO, Giuseppe; Menarini Ricerche, Via Tito Speri 10 Pomezia, Rome (IT). SIMONELLI, Cecilia; Menari- ni Ricerche, Via Sette Santi 3, Firenze (IT). BERTONI, Francesco; Institute of Oncology Research Fondazione per la Ricerca e la Cura sui Linfomi, Via Vela 6, 6500 Bellinzona (CH). PELLACANI, Andrea; Menarini Ricerche, Via Sette Santi 3, Firenze (IT). (74) Agent: DEHNS; St Bride's House, 10 Salisbury Square, London, Greater London EC4Y 8JD (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY Figure 9 IBRUTINIB (nM) II 0 III 15,625 MI 31,25 MI 62,5 MI 126 L 250 M. 500 1000 ma urn LY75_DM4 (nM) (57) : The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity. [Continued on next page] WO 2018/162727 Al MIDEDIMOMMIDIREEMOMOHEIDEMIHOEHMEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
priorityDate 2017-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419509191
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24821094

Total number of triples: 41.